Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 8Sarcoma 3Other hematologic neoplasm 3Plasma cell 2Genitourinary 2Dermatologic 2Thoracic 1Head & Neck 1CNS 1

Conditions

Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Neoplasms by Site 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × abexinostat × Plasma cell × Clear all
NCT01149668 2013-06-19

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Pharmacyclics LLC.

Phase 1 Completed
7 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00562224 2011-09-28

Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients

Pharmacyclics LLC.

Phase 1 Completed
36 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms by Site, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡